Floatz logo

ai-061

High Grade Serous Adenocarcinoma of Ovary

OncoC4, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

114 Active assets in the High Grade Serous Adenocarcinoma of Ovary cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Olaparib
Institute of Cancer Research, United Kingdom
Phase 3BB
Olaparib
National Cancer Institute (NCI)
Phase 2/3BB

View all 50 →

Same molecule, other indications

ai-061 is also rated in:

bile duct cancerDormant
CC
Indicative ·
43 / 100
View asset →
gastroesophageal junction adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
primary peritoneal carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →